The use of the LiDCORapid monitor to help guide how much fluids to give patients undergoing major head and neck cancer surgery

The use of LiDCORapid for fluid optimisation in patients undergoing major head and neck cancer surgery: a randomised controlled pilot study

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

ISRCTN

Registry ID

ISRCTN86457179

Enrollment

Registered

2011-03-07

Start date

2010-09-01

Completion date

Unknown

Last updated

2018-06-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Head and neck cancer Cancer Head and neck cancer

Interventions

Control group: Patients allocated to traditional fluid management. Tidal ventilation will be set at 8 ml/kg. Maintenance crystalloid will be administered as compound sodium lactate (Hartmanns) at a r

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Any patient (aged over 18 years, either sex) undergoing major head and neck cancer surgery with free tissue transfer reconstruction

Exclusion criteria

Exclusion criteria: 1. Patients declining to join the study 2. Patients with an arrhythmia that precludes the use of stroke volume variation (SVV), e.g., atrial fibrillation or significant sinus arrhythmia

Design outcomes

Primary

Measure	Time frame
Time to being declared medically fit for discharge (in hours from end of operation)	—

Secondary

Measure	Time frame
1. Length of stay in intensive treatment unit (ITU) (total time in ICU including note of readmission if occurs) 2. Total number of days in hospital 3. Readmissions within 30 days of surgery 4. Free tissue transfer complications 5. Return to theatre rate 6. Infective complications and their duration 7. Inpatient mortality Process outcome measures: 8. Difference in stroke volume and cardiac output between control and intervention groups at the beginning and end of the operation 9. Total volume of fluid given intra-operatively, colloid and crystalloid 10. Blood transfusion requirements (transfusion threshold of less than 8 g/dl unless patient has ischaemic heart disease in which case we would aim to keep Hb 9 - 11 g/dl per usual clinical practice	—

Measure

Time frame

1. Length of stay in intensive treatment unit (ITU) (total time in ICU including note of readmission if occurs) 2. Total number of days in hospital 3. Readmissions within 30 days of surgery 4. Free tissue transfer complications 5. Return to theatre rate 6. Infective complications and their duration 7. Inpatient mortality Process outcome measures: 8. Difference in stroke volume and cardiac output between control and intervention groups at the beginning and end of the operation 9. Total volume of fluid given intra-operatively, colloid and crystalloid 10. Blood transfusion requirements (transfusion threshold of less than 8 g/dl unless patient has ischaemic heart disease in which case we would aim to keep Hb 9 - 11 g/dl per usual clinical practice

—

Countries

United Kingdom

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Feb 4, 2026